Gilbert syndrome: a benign liver finding — the AU general practice approach

What Gilbert syndrome actually is

Bilirubin is a yellow pigment produced when the body breaks down haemoglobin from ageing red blood cells. The liver conjugates bilirubin — attaches glucuronic acid — to make it water-soluble for excretion into bile. Gilbert syndrome (named after the French physician Augustin Nicolas Gilbert) is an inherited reduction in the hepatic enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) that performs this conjugation step. Enzyme activity runs at roughly 30% of normal, so unconjugated bilirubin accumulates mildly in the circulation.

The result is a common, benign, lifelong tendency toward mildly elevated bilirubin — most pronounced during fasting, intercurrent illness, vigorous exercise, or dehydration. In Australian general practice, Gilbert syndrome appears almost daily: as an incidental finding on a routine blood panel ordered for another reason, as the explanation for recurrent mild yellow eyes in a young adult, or as a source of unnecessary patient anxiety when a bilirubin result is labelled “abnormal” without context.

Epidemiology: the UGT1A128 promoter polymorphism responsible for Gilbert syndrome is carried by approximately 30–35% of Anglo-Celtic Australians, with roughly 5–10% homozygous and showing the full phenotype. A different causal variant — UGT1A16 — predominates in East Asian-ancestry Australians. Gilbert syndrome is not associated with liver disease progression or reduced life expectancy; large cohort data suggest a modest association with lower cardiovascular disease rates, though this is not clinically actionable.

A. Core clinical — the AU general-practice framework

When to suspect Gilbert syndrome

Gilbert syndrome presents in general practice in one of three ways: (1) an incidental isolated bilirubin elevation on routine LFTs in an otherwise well young adult; (2) recurrent visible yellowing of the eyes coinciding with illness, fasting, or exertion; or (3) a young patient asking “why do my eyes go yellow when I’m sick?”

History to take:

• Timing: classical provocations are fasting (>24 hours), intercurrent viral or bacterial illness, vigorous or prolonged exercise, dehydration, menstruation, or perioperative fasting.
• Duration and course: typically since mid-adolescence or early adulthood, with fluctuations rather than progression.
• Associated symptoms: there should be none — no fatigue attributable to bilirubin, no pruritus, no dark urine, no pale stools, no right upper abdominal pain, no weight loss. Presence of any of these features removes Gilbert syndrome from the differential.
• Family history: ask if parents or siblings have had similar yellow eyes or a Gilbert diagnosis — the syndrome runs strongly in families.
• Medications: atazanavir, indinavir, raltegravir (HIV treatment), irinotecan (chemotherapy), rifampicin, probenecid, sulfasalazine — all raise unconjugated bilirubin by inhibiting UGT1A1 or hepatic uptake transporters.

Examination:

• Mild scleral icterus only at bilirubin >40–50 µmol/L, best appreciated in natural light against white sclera.
• No hepatomegaly, no splenomegaly, no stigmata of chronic liver disease — no spider naevi, palmar erythema, gynaecomastia, ascites, or asterixis. Any of these demands a full chronic liver disease workup.
• No lymphadenopathy, no pallor, no bruising.

Diagnostic investigation

The diagnosis rests on five biochemical criteria, per Sticova WJG 2013 and Bishop Mayo Clin Proc 2010:

1. Isolated unconjugated (indirect) hyperbilirubinaemia — unconjugated fraction ≥70% of total bilirubin; total bilirubin typically 30–50 µmol/L, rarely exceeds 80 µmol/L.
2. Normal ALT, AST, GGT, ALP, albumin, and INR — any abnormality removes Gilbert from the differential.
3. Normal full blood count (FBC) and reticulocyte count — excludes haemolysis.
4. Normal LDH and normal haptoglobin — raised LDH with low haptoglobin and raised reticulocytes indicates haemolysis, not Gilbert.
5. No structural hepatobiliary disease — no hepatomegaly, no biliary symptoms, no dark urine, no pale stools.

Practical pathology panel for a new presentation: LFTs (request the conjugated bilirubin fraction if not automatically reported), FBC, reticulocyte count, LDH, haptoglobin, iron studies including ferritin, and hepatitis B and C serology if not previously performed. TSH if fatigue or systemic symptoms are present. Repeat fasting LFTs in 4–8 weeks confirms the fluctuating-but-isolated pattern.

Not required: UGT1A1 genotype (the five biochemical criteria are sufficient for GP diagnosis), liver ultrasound (unless hepatomegaly or biliary symptoms are present), liver biopsy (never indicated in straightforward Gilbert), or fasting provocation test (superseded by biochemical criteria).

MBS items: GP attendances 23/36/44; LFTs 66512; FBC 65070; reticulocyte count 65129; LDH 66660; iron studies 66596. UGT1A1 genotyping is not currently MBS-funded for Gilbert syndrome diagnosis in Australia.

Management

No pharmacological treatment is required (eTG). The entire intervention is:

1. Confirm the diagnosis with the five-criterion blood panel.
2. Provide plain-English reassurance — explain that Gilbert syndrome is a common inherited variation in approximately 1 in 10–20 Australians, the liver is structurally and functionally normal, and the yellow tinge to the eyes during illness or fasting is harmless.
3. Eat regularly — avoid prolonged fasting, especially during illness, before elective surgery (per anaesthetic guidance), and during long-haul travel. Regular carbohydrate intake suppresses the fasting bilirubin spike.
4. Stay hydrated, particularly during exercise, hot weather, or illness.
5. Document the diagnosis prominently in the patient health summary so future clinicians do not misinterpret a bilirubin elevation during anaesthesia, illness, or blood transfusion.

Do not attribute fatigue to Gilbert syndrome. Controlled studies do not support a bilirubin–fatigue link (Bishop Mayo Clin Proc 2010). Investigate genuine causes: iron deficiency, B12 or folate deficiency, thyroid dysfunction, obstructive sleep apnoea, mood disorders, or coeliac disease.

B. Evidence appraisal

Question	Bottom line	Evidence quality
Biochemical criteria vs. genotyping for diagnosis	Five biochemical criteria are sufficient; genotype only for specific pharmacogenetic decisions (irinotecan, atazanavir)	🟢
Fasting provocation test	No longer recommended; superseded by biochemical criteria	🟢
Attribution of fatigue to Gilbert syndrome	Not supported by controlled data; investigate other causes	🟢
Phenobarbitone for cosmetic icterus	Not indicated; reserved for Crigler-Najjar type II	🟢
UGT1A1 genotyping before irinotecan	UGT1A1*28 homozygosity substantially increases severe neutropenia; dose reduction recommended (Innocenti JCO 2004)	🟢
Bilirubin as a cardiovascular protective biomarker	Interesting cohort associations; not clinically actionable	🟡

Key differentials: haemolysis (raised LDH, low haptoglobin, high reticulocytes, abnormal blood film), hepatocellular injury (any ALT/AST elevation), cholestatic disease (raised ALP/GGT, conjugated fraction dominant, dark urine, pale stools), Dubin-Johnson syndrome (conjugated hyperbilirubinaemia from ABCC2 mutation), Crigler-Najjar type II (bilirubin 100–340 µmol/L from coding-region UGT1A1 mutations — respond to phenobarbitone). Exclude drug-induced unconjugated hyperbilirubinaemia with a thorough medication history before confirming Gilbert.

C. Drug interactions — the pharmacogenetic issues that matter

UGT1A1 metabolises several clinically important drugs beyond bilirubin. For most medications, Gilbert syndrome is irrelevant, but two interactions require active management in Australian practice (Strassburg Pharmacogenomics 2008):

Irinotecan (chemotherapy). Irinotecan is activated to SN-38, which is inactivated by UGT1A1 glucuronidation. In UGT1A128 homozygotes — that is, patients with Gilbert syndrome — SN-38 accumulates to higher levels, substantially increasing the risk of severe neutropenia and diarrhoea (Innocenti JCO 2004). US FDA labelling mandates dose reduction in known UGT1A128 homozygotes. Australian oncology practice often includes UGT1A1 genotyping before high-dose irinotecan. GP action: flag Gilbert syndrome explicitly in referral letters to oncologists before bowel cancer, lung cancer, or other chemotherapy regimens containing irinotecan.

Atazanavir and indinavir (HIV treatment). These HIV protease inhibitors inhibit UGT1A1, causing unconjugated hyperbilirubinaemia — and more pronounced visible jaundice in Gilbert patients who already have reduced UGT1A1 activity. The jaundice is cosmetic and not a sign of liver toxicity. If visible yellow eyes are unacceptable to the patient, the treating HIV physician may consider switching to an integrase-inhibitor-based regimen (dolutegravir, bictegravir) that does not affect UGT1A1. Do not discontinue effective ART based on Gilbert-related icterus alone.

Paracetamol. Therapeutic doses (≤4 g/day in healthy adults; ≤3 g/day in older adults) are safe in Gilbert syndrome (Bishop Mayo Clin Proc 2010). Paracetamol overdose risk is not increased.

Other UGT1A1 substrates — raltegravir, gemfibrozil, ezetimibe, rifampicin — can cause modest bilirubin rises in Gilbert patients. These are usually trivial and not a reason to withhold effective treatment; document Gilbert status in the patient record so clinicians can contextualise any bilirubin elevation.

D. Australian operations

eTG and NPS MedicineWise both confirm the no-treatment approach to Gilbert syndrome. Key Australian operational points:

Documentation priority. Record the Gilbert diagnosis prominently in the health summary and medication record, visible to anaesthetists, emergency clinicians, and downstream prescribers. A perioperative bilirubin elevation in a fasting Gilbert patient should not trigger unnecessary hepatobiliary investigation unless liver enzymes are also abnormal.

UGT1A1 genotyping. Not MBS-funded as a stand-alone diagnostic test in Australia. Patients needing it for irinotecan dose planning access it through their oncology service. Private testing is available through major Australian pathology providers (approximately AUD 100–250). Provide pre-test counselling per the RACGP Genomics in General Practice framework, noting the current Australian genetic-testing moratorium and its potential implications for life insurance disclosure.

Blood donation. Gilbert syndrome is not a deferral criterion. Eligible patients can donate through Australian Red Cross Lifeblood under standard criteria.

No GPCCMP required. Gilbert syndrome does not qualify as a chronic disease requiring a GP Management Plan, Team Care Arrangement, or allied-health referral. A single consultation establishing the diagnosis, plus a review of repeat fasting LFTs in 4–8 weeks, closes the episode for most patients.

Telehealth. Follow-up for reassurance, results discussion, or further questions is appropriate via telehealth under the standard existing-relationship rule. Gilbert syndrome is well-suited to telehealth review.

No PBS treatment. There is no PBS-listed medication for Gilbert syndrome — the condition does not require pharmacotherapy.

E. Special populations

Adolescents. Most patients are first identified between mid-adolescence and early adulthood. Hormonal changes at puberty amplify UGT1A1 activity differences — males with the same genotype tend to express higher bilirubin levels than females. An “abnormal liver test” at this age can generate significant anxiety; targeted and confident reassurance from the GP is the most important intervention.

East Asian-ancestry Australians. The UGT1A16 (p.Gly71Arg) coding-region variant — not the TA7 promoter polymorphism — is the predominant Gilbert allele in Japanese, Korean, and Chinese populations. Standard laboratory assays for UGT1A128 may not detect this variant. If diagnostic doubt persists in a patient of East Asian ancestry with otherwise consistent biochemistry, refer to a hepatologist or pharmacogenetics service familiar with UGT1A1*6 testing.

Neonates. UGT1A1*28 amplifies physiological neonatal jaundice and interacts with G6PD deficiency and ABO incompatibility to prolong unconjugated hyperbilirubinaemia. Neonatal bilirubin management follows standard phototherapy thresholds regardless of Gilbert status; genotyping may be considered in neonates with severe or prolonged jaundice, but clinical bilirubin monitoring is the primary approach.

Pregnancy. Gilbert syndrome does not cause pregnancy complications and requires no altered antenatal monitoring. If bilirubin rises in pregnancy, distinguish from intrahepatic cholestasis of pregnancy (raised bile acids, pruritus, elevated ALT), HELLP syndrome (thrombocytopenia, elevated liver enzymes, raised LDH), and pre-eclampsia — none of these are Gilbert syndrome.

Patients starting irinotecan. As outlined in Section C, UGT1A1*28 homozygosity increases irinotecan toxicity and warrants dose adjustment. This is the one clinical setting in which pharmacogenetic testing for Gilbert syndrome has a formal indication, managed by the treating oncologist.

When to escalate

Refer to hepatology or gastroenterology when:

• Bilirubin consistently exceeds 80–100 µmol/L — consider Crigler-Najjar type II, haemolysis, or biliary disease.
• Any liver enzyme (ALT, AST, ALP, GGT) is abnormal — Gilbert syndrome does not explain elevated hepatocellular or cholestatic markers.
• Conjugated (direct) bilirubin fraction is dominant (>30–50% of total) — points to Dubin-Johnson syndrome, Rotor syndrome, biliary obstruction, or hepatocellular disease, not Gilbert.
• Haemolysis markers are abnormal: raised LDH, low haptoglobin, raised reticulocytes, or abnormal blood film.
• Biliary symptoms are present: dark urine, pale stools, pruritus, or right upper abdominal pain — none of these belong to Gilbert syndrome.
• Diagnostic uncertainty persists after the five-criterion workup.

Refer to oncology when irinotecan-based chemotherapy is planned — flag Gilbert status explicitly so the oncologist can arrange UGT1A1 genotyping and dose planning.

Emergency department. New-onset jaundice with fever and rigors (possible cholangitis), signs of acute liver failure, altered conscious state, or haemodynamic compromise is a medical emergency and is never Gilbert syndrome until proven otherwise.

What this article is and is not

This is general health information drawn from current Australian general practice guidelines — Therapeutic Guidelines, Australian Medicines Handbook, NPS MedicineWise, RACGP Genomics in General Practice — and peer-reviewed hepatology literature. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about investigation and management are made with your own GP and treating clinicians.

For Australian consumer information: HealthDirect — Gilbert syndrome, Better Health Channel — Gilbert syndrome.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Hepatology: Gilbert syndrome
2. RACGP — Genomics in general practice
3. Australian Medicines Handbook
4. NPS MedicineWise
5. HealthDirect — Gilbert syndrome
6. Better Health Channel — Gilbert syndrome
7. Bosma — Genetic basis of UGT1A1 reduction in Gilbert’s syndrome (NEJM 1995)
8. Sticova — Bilirubin metabolism and clinical implications (World J Gastroenterol 2013)
9. Bishop — Gilbert syndrome clinical pearls (Mayo Clin Proc 2010)
10. Innocenti — UGT1A1 variants and irinotecan neutropenia (J Clin Oncol 2004)
11. Strassburg — Pharmacogenetics of Gilbert’s syndrome (Pharmacogenomics 2008)
12. Australian Red Cross Lifeblood